Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
IO Month - session 3 - 952x200

Resistance to immunotherapies: Turning cold into hot - firing up the TME

Watch on demand our second session of 'New Directions in Immuno-oncology: Response and Resistance' held on February 10, 2021

​​Webinar objectives

  • Discover how hypoxia drives tumor immune suppression and immunotherapy resistance
  • Discuss overcoming resistance to STING-induced anti-tumour immunity
  • Utilize in vivo labelling system to identify and isolate cells from the metastatic niche

​Abcam is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.  Interested in receiving P.A.C.E credit for this educational session? Request credit here!


Speakers

  • Michael Curran, MD Anderson Cancer Center, USA​
    • Hypoxia drives tumor immune suppression and immunotherapy resistance
    • Timestamp: 2:35 - 37:02
  • Andrew Mellor, Newcastle University, UK​
    • ​Overcoming resistance to STING-induced anti-tumour immunity
    • Timestamp: 38:06 - 1:06:45
  • Luigi Ombrato, Barts Cancer Institute - Queen Mary University of London, UK
    • ​Tumour microenvironment de-construction: a tool to study inter-cellular interactions in the niche
    • Timestamp: 1:07:40 - 1:32:30

Contact
​Have a question? Please contact the Abcam Events Team.